Pentixapharm AG

About Pentixapharm AG

Pentixapharm is dedicated to improving the lives of patients through first-in-class radiopharmaceutical approaches. The company focuses on innovative drug development with a strong emphasis on research and development, employing a team of 80 with over 80% focused on R&D.

Products & Services

CXCR4 Compound:Extensively studied in over 150 scientific papers and administered to more than 2,000 patients.

Phase-III-ready Drug Candidates:Two drug candidates ready for Phase III clinical trials.

GT-008:A first-in-class glycan-dependent anti-CD24 monoclonal antibody radiopharmaceutical for solid tumors.

PentixaTher:A Yttrium-90-based radiopharmaceutical under a contract manufacturing agreement with Eckert & Ziegler SE.

Specialties

Radiopharmaceuticals Drug Development Clinical Research Oncology (Solid Tumors)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Transaction T: - FT: Transaction	A: 7447000 MR: - FA: 6.77 million Euro FAN: 7447000	D: 2025-01-07 FD: 2025-01-07	1 investors

Transaction Latest

2025-01-07

$7.4M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dr. Dirk Pleimes

Group CEO & CMO

H

Henner Kollenberg

CBO

S

Simone Pickel

Head Clinical Therapy

D

Dr. Anna Aldinger

Head Clinical Diagnostics

A

Alessandra Bierwagen

Head Regulatory

D

Dr. Antje Danielczyk

Head of Quality Management and Operations

View 17 more team members with Pro

Unlock Full Team Directory

Recent News

Pentixapharm AG Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised